EBS vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 13, 2026

EBS

54.0
AI Score
VS
EBS Wins

PCRX

50.6
AI Score

Investment Advisor Scores

EBS

54score
Recommendation
HOLD

PCRX

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric EBS PCRX Winner
Revenue 500.40M 546.43M PCRX
Net Income -206.10M 36.09M PCRX
Net Margin -41.2% 6.6% PCRX
Operating Income -151.90M 33.44M PCRX
ROE -65.8% 5.1% PCRX
ROA -20.7% 3.0% PCRX
Total Assets 995.20M 1.20B PCRX
Cash 175.70M 246.96M PCRX
Debt/Equity 1.64 0.41 PCRX
Current Ratio 4.58 4.68 PCRX
Free Cash Flow 114.60M 125.53M PCRX

Relative Price Performance (Last 90 Days)

EBS 1M: -19.4% · 3M: +28.7% PCRX 1M: +0.4% · 3M: +56.9%

Current Technical Phase

EBS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 38

RSI (14): 38.4 · Price: $5.79

PCRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (17.4% over 20 days), RSI 83

RSI (14): 82.6 · Price: $36.46

Fundamentals Snapshot

Metric EBS PCRX
Market Cap — —
Forward P/E 5.5 10.5
Trailing P/E — 39.2
Revenue (TTM) — —
Revenue Growth -52.4% -1.6%
Gross Margin 43.4% 78.0%
Operating Margin 5.8% 4.1%
EPS -5.00 0.93
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, EBS is currently the stronger investment candidate with a higher AI composite score (54.0/100 vs. 50.6/100), supported by its current technical phase (EBS: Neutral, PCRX: Markup) and fundamental profile.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.